<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00589927</url>
  </required_header>
  <id_info>
    <org_study_id>2007-0003</org_study_id>
    <nct_id>NCT00589927</nct_id>
  </id_info>
  <brief_title>Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent</brief_title>
  <acronym>DECLARELONG</acronym>
  <official_title>Comparison of Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent Implantation For Long Coronary Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether the cilostazol reduce neointimal hyperplasia after ZES
      (Zotarolimus-eluting stents) implantation, the investigators performed
      double-blind,randomized, multicenter, prospective study compared triple antiplatelet therapy
      (aspirin plus clopidogrel plus cilostazol) and dual antiplatelet therapy (aspirin plus
      clopidogrel) for 8 months in patients with long coronary lesion treated with ZES.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Use of drug-eluting stent (DES) has reduced the incidence of restenosis rate and the need for
      repeat revascularization compared to using bare metal stents. DES implantation also
      significantly reduced the angiographic restenosis in patients with long coronary
      lesions.However, although the use of DES has decreased the effect of lesion length on
      restenosis, the restenosis after DES implantation of long coronary lesions remain at a higher
      risk of restenosis.

      Cilostazol, a phosphodiesterase III inhibitor, has been known to reduce smooth muscle
      proliferation and intimal hyperplasia after endothelial injury and restenosis after balloon
      angioplasty and bare-metal stent (BMS) implantation when compared with aspirin and
      clopidogrel or ticlopidine. Recently, the impact of 6-month cilostazol treatment in addition
      to aspirin and clopidogrel on neointimal hyperplasia after sirolimus-(SES) or
      paclitaxel-eluting stent (PES) implantation for long-coronary lesions has been evaluated in
      our institution. It reported that cilostazol treatment achieved primary end point (in-stent
      late loss) and reduced need of target lesion revascularization without significant adverse
      drug-side effects with open-label design, which suggest that 6-month treatment of cilostazol
      effectively inhibits the neointimal hyperplasia after DES implantation and can be safely
      applied to the patients or lesions with higher risk of restenosis such as diabetes and long
      lesions.However, our study was done in unblinded manner and might underestimate the
      angiographic results due to relatively short-term follow-up angiographic follow-up(6-month.

      Recently commercially available new-DES, zotarolimus-eluting stent (ZES) demonstrated
      significant reduction of restenosis and cardiac events during 9-month. However, it has not
      been tested that 8-month treatment of cilostazol also effectively inhibits the neointimal
      hyperplasia after ZES implantation in patients with long coronary lesions. Therefore, to
      evaluate whether the cilostazol reduce neointimal hyperplasia after ZES implantation, the
      investigators performed double-blind, randomized, multicenter, prospective study compared
      triple antiplatelet therapy (aspirin plus clopidogrel plus cilostazol) and dual antiplatelet
      therapy (aspirin plus clopidogrel) for 8 months in patients with long coronary lesion treated
      with ZES.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic in-stent late loss</measure>
    <time_frame>8-months after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of death, MI, and target lesion or vessel revascularization at 12 months, In-stent and in-stent restenosis at 8 months, In-segment late loss at 8 months Adverse side effects during treatment</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">486</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cilostazol</intervention_name>
    <description>cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months</description>
    <arm_group_label>cilostazol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical 1) Patients with angina and documented ischemia or patients with documented
             silent ischemia 2) Patients who are eligible for intracoronary stenting 3) Age &gt;18
             years, &lt;75 ages

          2. Angiographic 1) De novo lesion 2) Percent diameter stenosis â‰¥50% 3) Reference vessel
             size &gt;2.5 mm by visual estimation 4) Lesion length &gt;25 mm by visual estimation that is
             required for long Endeavor stent implantation (planned total stent length &gt;30mm)

        Exclusion Criteria:

          1. History of bleeding diathesis or coagulopathy

          2. Pregnant

          3. Known hypersensitivity or contra-indication to contrast agent, heparin, sirolimus and
             paclitaxel

          4. Limited life-expectancy (less than 1 year) due to combined serious disease

          5. ST-elevation acute myocardial infarction

          6. Characteristics of lesion 1) Left main disease 2) In-stent restenosis 3) Graft vessels

          7. Hematological disease (Neutropenia &lt;3000/mm3, Thrombocytopenia &lt;100,000/mm3)

          8. Hepatic dysfunction, liver enzyme (ALT and AST) elevation &gt;3 times normal

          9. Renal dysfunction, creatinine &gt;2.0mg/dL

         10. Contraindication to aspirin, clopidogrel or cilostazol

         11. planned bifurcation stenting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Wook Park, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Hospital, Cheonan</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangwon National University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital,</name>
      <address>
        <city>PyeongChon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hangang Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul Veterans Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2007</study_first_submitted>
  <study_first_submitted_qc>December 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <last_update_submitted>March 17, 2010</last_update_submitted>
  <last_update_submitted_qc>March 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Seong-Wook Park, MD, PhD</name_title>
    <organization>Asan Medical Center</organization>
  </responsible_party>
  <keyword>stents</keyword>
  <keyword>cilostazol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

